Nutriband Inc. develops prescription transdermal pharmaceutical products, with recurring updates centered on its AVERSA abuse-deterrent transdermal technology and a lead abuse-deterrent fentanyl transdermal system. The technology incorporates aversive agents into patches to address abuse, diversion, misuse and accidental exposure involving drugs with abuse potential, including opioids and stimulant drugs.
Company news also covers product distribution activity for kinesiology tapes and mosquito repellent patches, regulatory and intellectual-property steps tied to transdermal products, shareholder meeting matters, and corporate updates involving operating subsidiaries and Nasdaq-listed common stock and warrants.
Nutriband (NTRB) received $1,753,274.53 in proceeds from the exercise of warrants, providing funding for its AVERSA Fentanyl development plans.
A total of 272,671 NTRBW warrants were exercised at $6.43. The warrants expired on September 30 without an extension, leaving no remaining tradeable warrants. Nutriband plans to use the proceeds primarily for remaining clinical development of AVERSA Fentanyl and submission of a new drug application to the FDA for marketing approval. The company cites an estimate that the product could reach $80 million to $200 million in peak annual US sales.
Nutriband (NTRB) has filed a new U.S. utility patent application covering improvements to its AVERSA abuse-deterrent technology for transdermal patches.
The non-provisional application, filed with the U.S. Patent and Trademark Office, covers improved aversive formulations and coating application methods. AVERSA uses a coating intended to deter oral abuse through taste aversion and reduce accidental exposure. Nutriband says that, if granted, the new patent could extend worldwide patent protection for AVERSA-based products, including AVERSA FENTANYL, to 2046. The technology already has patents issued in 46 countries. The filing is an application, not a granted patent.
Nutriband (NTRB) marked five years on Nasdaq with a shareholder letter outlining AVERSA Fentanyl development milestones and its next priorities. The 2021 offering warrants expired on September 30, 2026, without extension or repricing and were removed from the NTRBW listing. The company has no debt.
Commercial manufacturing process scale-up for AVERSA Fentanyl was completed in June 2025. Nutriband plans to manufacture supplies for a Human Abuse Liability study, file an Investigational New Drug application with the FDA and initiate clinical studies, with development directed toward a New Drug Application filing. It also plans a nonprovisional patent application that could extend AVERSA-based product protection to 2046. The retrospective includes a 2025 preferred-stock dividend and record Q3 2024 revenue of $645,796, up 51% year over year.
Nutriband (NTRB) CEO Gareth Sheridan appears in a new documentary by Nick Shirley about the U.S. opioid crisis.
Sheridan discusses Nutriband's AVERSA patch technology, which the company says is designed to reduce abuse, misuse, diversion and accidental exposure involving medications with abuse potential.
Nutriband (NTRB) appointed former U.S. Navy SEAL Robert J. O'Neill to its advisory board on September 25, 2026.
O'Neill served 16 years in the Navy, including eight with SEAL Team Six, and has advocated for veterans' access to emerging health treatments. Nutriband's advisory board supports executives on strategy, growth and execution as the company advances its abuse-deterrent skin patch pipeline, including AVERSA Fentanyl. That product remains subject to approval.
Nutriband (NTRB) confirmed that its outstanding Nasdaq-listed warrants (NTRBW) will expire as scheduled on September 30, 2026 at 5PM ET, with no extension or repricing.
Warrant holders may exercise at a strike price of $6.43 per share until the deadline. There are 910,904 warrants outstanding, representing potential proceeds of $5,856,112 to the company if fully exercised. Warrants not exercised by the expiration time will lapse in full and be removed from the NTRBW Nasdaq listing. The company advises shareholders and warrant holders to act before the deadline if they intend to exercise.
Nutriband (NTRB) CEO Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on September 16. The event will take place at Nasdaq MarketSite in New York.
Nutriband (NTRB) received a USPTO Notice of Publication for commercial brand name trademarks for its lead abuse-deterrent fentanyl transdermal system, dated September 2, 2026.
The trademarks will appear in the USPTO Trademark Official Gazette, after which a 30‑day opposition period applies before a potential Notice of Allowance. Nutriband plans to secure full intellectual property rights for these commercial brand names in the United States and internationally and to submit the proposed brand name and product labeling to the FDA and other global regulators. The fentanyl patch uses AVERSA™ abuse‑deterrent technology and is projected to have potential peak annual US sales of $80 million to $200 million, supported by patents issued in 46 countries.
Nutriband (NASDAQ:NTRB)/b) announced that CEO and Co-Founder will present in the CEO Spotlight at the 2026 Georgia Life Sciences Summit on August 26, 2026. The Summit, held August 25–26 at the Sandy Springs Performing Arts Centre in Sandy Springs, Georgia, convenes leaders from biotechnology, medical technology, research, manufacturing, and investment.
Nutriband (NASDAQ:NTRB) and its Active Intelligence subsidiary will participate in the June 2026 ECRM conference, meeting buyers from Walmart, Walgreens, Amazon, Cardinal Health and other major retailers.
Active Intelligence will showcase its expanding AI Tape line and launch new AI Performance Tape, AI Energy Patches, and AI Sleep products.